The cost of nephroblastoma treatment in South Africa : a very cost-effective investment with guidelines for the rest of Africa

dc.contributor.authorStefan, Daniela Cristinaen_ZA
dc.contributor.authorStones, D. K.en_ZA
dc.contributor.authorVan Zyl, A.en_ZA
dc.contributor.authorUys, R.en_ZA
dc.date.accessioned2016-01-25T09:06:31Z
dc.date.available2016-01-25T09:06:31Z
dc.date.issued2014-11-13
dc.descriptionPlease cite as follows: Stefan, D. C., Stones, D. K., Van Zyl, A. & Uys, R. 2014. The cost of nephroblastoma treatment in South Africa: a very cost-effective investment with guidelines for the rest of Africa. South African Journal of Child Health, 8(4):128-132, doi:10.7196/SAJCH.749.en_ZA
dc.descriptionThe original publication is available at http://www.sajch.org.za/index.php/SAJCH
dc.description.abstractBackground. Nephroblastoma is one of the most common childhood malignancies in Africa, but with a survival rate significantly lower than in developed countries. In African countries with a small gross domestic product (GDP) per capita, the cost of treating nephroblastoma may be prohibitive. Objectives. To determine the direct costs of treatment of nephroblastoma in South Africa (SA) and to propose a more cost-effective approach to investigations and treatment for the disease in Africa. Methods. Data from 2000 - 2010 from two SA paediatric oncology units were retrospectively analysed. The costs included investigations, chemotherapy and radiotherapy, comparing early-v. advanced-stage disease. In both units, the nephroblastoma International Society of Paediatric Oncology (SIOP) protocol was used. Results. Stage I disease was the most common, followed by stage IV. The total cost of diagnosis, staging and treatment of stage I disease was ZAR9 304.97 (EUR882.80 or USD1 093.40), compared with a five-times higher cost for stage IV (ZAR48 293.62 (EUR4 581.9 or USD5 674.9)). Treating one patient averted more than 32 disability adjusted life years. The investigation and treatment of early- and advanced-stage disease is very cost-effective when compared with the local GDP per capita. Conclusion. The cost of investigation and treatment of nephroblastoma remains a challenge everywhere, but especially in Africa. However, it is a very cost-effective disease to treat and children in Africa should not be denied treatment.en_ZA
dc.description.urihttp://www.sajch.org.za/index.php/SAJCH/article/view/749
dc.description.versionPublisher's versionen_ZA
dc.format.extent5 pagesen_ZA
dc.identifier.citationStefan, D. C., Stones, D. K., Van Zyl, A. & Uys, R. 2014. The cost of nephroblastoma treatment in South Africa: a very cost-effective investment with guidelines for the rest of Africa. South African Journal of Child Health, 8(4):128-132, doi:10.7196/SAJCH.749.en_ZA
dc.identifier.issn1999-7671 (online)
dc.identifier.issn1994-3032 (print)
dc.identifier.otherdoi:10.7196/SAJCH.749
dc.identifier.urihttp://hdl.handle.net/10019.1/98210
dc.language.isoen_ZAen_ZA
dc.publisherHealth & Medical Publishing Groupen_ZA
dc.rights.holderSouth African Journal of Child Healthen_ZA
dc.subjectNephroblastoma -- Treatment -- South Africaen_ZA
dc.subjectNephroblastoma -- Treatment -- Costs -- South Africaen_ZA
dc.subjectNephroblastoma -- Treatment -- Costs -- Africaen_ZA
dc.titleThe cost of nephroblastoma treatment in South Africa : a very cost-effective investment with guidelines for the rest of Africaen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
stefan_cost_2014.pdf
Size:
115.02 KB
Format:
Adobe Portable Document Format
Description:
Download article
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description: